Low prices and an uncertain future for Movkir

On July 29, 2020, Movkir’s lung became The first remote monitoring tool for common law reimbursement in France.

It is a first class medical device (MD) in the form of a web application for remote medical monitoring of relapses and complications in patients with non-progressive lung cancer.

Concretely, each week it sends an email to the patient inviting them to answer a 12-item questionnaire (on mobile, computer or tablet). The program analyzes the responses taking into account the responses of the previous weeks, and if a risk of recurrence or complications is detected, an alert is sent to the referring specialist.

As a reminder, the device must be prescribed by an oncologist, pulmonologist or surgeon and accompanied by a letter addressed to the treating physician. The patient gives his consent to the referring health professional, who also accompanies him in using the instrument.

To access the rest of the article, you must accept performance and tracking cookies. It allows us to anonymously aggregate statistics we share with our advertisers. Thanks to advertising, this site is funded and the articles written by our journalists are available to you for free.

To change your cookie settings, Press here.

Did you like this article?

Subscribe to our newsletter and receive weekly digital news from the health industries

See also  Lassa fever, whose symptoms are similar to Ebola, causes one patient to die in England

You May Also Like

About the Author: Irene Alves

"Bacon ninja. Guru do álcool. Explorador orgulhoso. Ávido entusiasta da cultura pop."

Leave a Reply

Your email address will not be published. Required fields are marked *